Advertisement

Medical and Surgical Treatment of the Skin in Epidermolysis Bullosa

  • Andrew N. Lin
  • D. Martin Carter

Abstract

Although no cure exists for any form of EB, many agents have been tried in the hope of uncovering therapeutic success. In this chapter we review treatments aimed specifically at decreasing cutaneous blistering. General principles of wound care as applied to the EB patient and treatments designed to improve extracutaneous complications are reviewed elsewhere in this text.

Keywords

Epidermolysis Bullosa Blister Formation Acta Derm Epidermolysis Bullosa Acquisita Dystrophic Epidermolysis Bullosa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carter DM, Caldwell D, Varghese M, Balin AK. Effectiveness of Bactroban ointment in chronic skin infection: report of a clinical study. In: Dobson RL, Leyden JJ, Noble WC, Price JD, eds. Bactroban (Mupirocin): Proceedings of an International Symposium. Amsterdam: Excerpta Medica; 1985: 228–234.Google Scholar
  2. 2.
    Caldwell D, Carter DM, Lin A, Varghese M. Topical mupirocin in epidermolysis bullosa: safety and efficacy of long-term treatment. In: Wood C, eds. Proceedings of the Royal Society of Medicine; Round Table Series, Number 4. Oxford: Alden Press; 1986:12–26.Google Scholar
  3. 3.
    Lin AN, Caldwell D, Varghese M, Pratt L, Balin A, Carter DM. Efficacy of long term mupirocin therapy in epidermolysis bullosa and its effect on growth and lifespan on cultured fibroblasts. J Invest Dermatol. 1986; 87:152.Google Scholar
  4. 4.
    Rahman M, Noble WC, Cookson B. Mupirocin-resistant Staphylococcus aureus (letter). Lancet. 1987;2:387.Google Scholar
  5. 5.
    Moy J, Caldwell-Brown D, Lin AN, Pappa KA, Carter DM. Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol. 1990;22:893–895.PubMedGoogle Scholar
  6. 6.
    Bauer EA, Eisen AZ. Recessive dystrophic epidermolysis bullosa: evidence for increased collagenase as a genetic characteristic in cell culture. J Exp Med. 1978;148:1378–1387.PubMedGoogle Scholar
  7. 7.
    Eisenberg M, Stevens LJ, Schofield PJ. Epidermolysis bullosa: new therapeutic approaches. Austr J Dermatol. 1978; 19:1–8.Google Scholar
  8. 8.
    Bauer EA, Tabas M. A perspective on the role of collagenase in recessive dystrophic epidermolysis bullosa. Arch Dermatol. 1988; 124:734–736.PubMedGoogle Scholar
  9. 9.
    Bauer EA, Cooper TW, Tucker DR, Esterly NB. Phenytoin therapy of recessive dystrophic epidermolysis bullosa: clinical trial and proposed mechanism of action on collagenase. N Engl J Med. 1980; 303:776–781.PubMedGoogle Scholar
  10. 10.
    Cooper TW, Bauer EA. Therapeutic efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Arch Dermatol. 1984; 120:490–495.PubMedGoogle Scholar
  11. 11.
    Lin AN., Stern RB, Caldwell-Brown D, Carter DM, collaborators. Phenytoin for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 1989; 92:472.Google Scholar
  12. 12.
    Winberg J-O, Real C, Gedde-Dahl Jr T, Bauer EA. Collagenase expression in skin fibroblasts from families with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 1989; 92:82–85.PubMedGoogle Scholar
  13. 13.
    Kero M. Epidermolysis bullosa in Finland: clinical features, morphology and relation to collagen metabolism. Acta Derm Venereol (Stockh). 1984; Suppl 110:1–51.Google Scholar
  14. 14.
    Kero M, Palotie A, Peltonen L. Collagen metabolism in two rare forms of epidermolysis bullosa. Br J Dermatol. 1984; 110:177–184.PubMedGoogle Scholar
  15. 15.
    Fine J-D, Johnson L. Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa. Arch Dermatol. 1988; 124:1402–1406.PubMedGoogle Scholar
  16. 16.
    Rogers RB, Yancey KB, Allen BS, Guill MF. Phenytoin therapy for junctional epidermolysis bullosa. Arch Dermatol 1983; 119:925–926.PubMedGoogle Scholar
  17. 17.
    Guill MF, Wray BB, Rogers RB, Yancey KB, Allen BS. Junctional epidermolysis bullosa: treatment with phenytoin. Am J Dis Child. 1983; 137:992–994.PubMedGoogle Scholar
  18. 18.
    Bergfeld WF, Orlowski JP. Epidermolysis bullosa letalis and phenytoin (letter). J Am Acad Dermatol 1982;7:275–276.PubMedGoogle Scholar
  19. 19.
    Winer MN, Orman JM. Epidermolysis bullosa: a suggestion as to possible causation. Arch Dermatol Syphilol. 1945; 52:317–321.Google Scholar
  20. 20.
    Thompson RG, Leedham CL, Hailey H. Epidermolysis bullosa hereditaria. South Med J. 1949;42:647–653.PubMedGoogle Scholar
  21. 21.
    Hall-Smith SP, Daunt FO’N. Recurrent bullous eruption of feet: report of a case. Lancet. 1948;1:66–67.PubMedGoogle Scholar
  22. 22.
    Kumar K, Kumar R. Epidermolysis bullosa dystrophica et albo-papuloidea Pasini in an Indian: a case report. Dermatologica. 1973; 147:137–143.PubMedGoogle Scholar
  23. 23.
    DesGrosseilliers J-P, Brisson P. Localized epidermolysis bullosa: report of two cases and evaluation of therapy with glutaraldehyde. Arch Dermatol. 1974; 109: 70–72.Google Scholar
  24. 24.
    Tkach JR. Treatment of recurrent bullous eruption of the hands and feet (Weber-Cockayne Disease) with topical aluminum chloride (letter). J Am Acad Dermatol. 1982;6:1095–1096.PubMedGoogle Scholar
  25. 25.
    Jennings JL. Aluminum chloride hexahydrate treatment of localized epidermolyis bullosa. Arch Dermatol 1984; 120:1382.PubMedGoogle Scholar
  26. 26.
    Younger IR, Priestley GC, Tidman MJ. Aluminum chloride hexahydrate and blistering in epidermolysis bullosa simplex. J Am Acad Dermatol. 1990; 23:930–931.PubMedGoogle Scholar
  27. 27.
    Niemi K-M, Kero M, Kanerva L, Mattila R. Epidermolysis bullosa simplex: a new histologic subgroup. Arch Dermatol. 1983; 119:138–141.PubMedGoogle Scholar
  28. 28.
    Rosset M. Epidermolysis bullosa in the newborn. Can Med Assoc J 1956; 75: 507–509.PubMedGoogle Scholar
  29. 29.
    Silver HK. Epidermolysis bullosa hereditaria letalis: report of a case surviving for two and a half years. Arch Dis Child. 1957;32:216–219.PubMedGoogle Scholar
  30. 30.
    Moynahan EJ. Epidermolysis bullosa affecting the buccal and pharyngeal mucosa. Proc R Soc Med. 1963; 56:885–888.PubMedGoogle Scholar
  31. 31.
    Fattah AA. Epidermolysis bullosa hereditaria letalis (Herlitz). Dermatologica. 1966;133:475–481.PubMedGoogle Scholar
  32. 32.
    Pearson RW, Potter B, Strauss F. Epidermolysis bullosa hereditaria letalis: clinical and histologic manifestations and course of the disease. Arch Dermatol. 1974;109:349–355.PubMedGoogle Scholar
  33. 33.
    Schachner L, Lazarus GS, Dembitzer H. Epidermolysis bullosa hereditaria letalis: pathology, natural history and therapy. Br J Dermatol. 1977;96:51–58.PubMedGoogle Scholar
  34. 34.
    Walther T. Epidermolysis bullosa hereditaria letalis: a review and report of two own cases. Ann Ped Int Rev Pediatr. 1953; 180:382–392.Google Scholar
  35. 35.
    Leland LS, Hirschl D. Epidermolysis bullosa hereditaria letalis in newborn twins: report of two cases with failure to respond favourably to cortisone. Am J Dis Child. 1954;87:321–327.Google Scholar
  36. 36.
    Henderson AT. Epidermolysis bullosa hereditaria letalis: report of a case failing to respond to cortisone. J Pediatr. 1955;46:186–191.PubMedGoogle Scholar
  37. 37.
    Roberts MH, Howell DRS, Bramhall JL, Reubner B. Epidermolysis bullosa letalis: report of three cases with particular reference to the histopathology of the skin. Pediatrics. 1960;25:283–290.PubMedGoogle Scholar
  38. 38.
    Lowe LB. Hereditary epidermolysis bullosa. Arch Dermatol. 1967;95:587–595.PubMedGoogle Scholar
  39. 39.
    Bergenholtz A, Olsson O. Epidermolysis bullosa hereditaria letalis: a survey of the literature and report of 11 cases. Acta Derm Venereol (Stockh). 1968; 48: 220–241.Google Scholar
  40. 40.
    Oakley CA, Wilson N, Ross JA., Barnmetson RStC. Junctional epidermolysis bullosa in two siblings: clinical observations, collagen studies and electron microscopy. Br J Dermatol. 1984; 111:533–543.PubMedGoogle Scholar
  41. 41.
    Gill S. Epidermolysis bullosa dystrophica with peculiar mutilation of hands. Israel Med J. 1961;20:11–12.Google Scholar
  42. 42.
    Taft EH. Dystrophic epidermolysis bullosa. Austr. J. Dermatol. 1969; 10:189–190.Google Scholar
  43. 43.
    Tidman MJ, Marsden RA. Severe dominant dystrophic epidermolysis bullosa. Br J Dermatol. 1985; 113(Suppl 29): 80–81.Google Scholar
  44. 44.
    Drury RE, Prieto Jr A. Epidermolysis bullosa dystrophica. Report of two cases within a family group. Oral Surg Oral Med Oral Pathol. 1964; 18:544–551.PubMedGoogle Scholar
  45. 45.
    Caldiera Jde B, Costa MHL. Epidermolysis bullosa hereditaria: clinical trial with fluocinonide FAPG 0.05% in five cases. Acta Derm Venereol (Stockh). 1972; Suppl 67:88–90.Google Scholar
  46. 46.
    Enell H, Lindeas K. Epidermolysis bullosa hereditaria dystrofica. I. Treatment with cortisone. Acta Derm Venereol (Stockh). 1953;33:488–496.Google Scholar
  47. 47.
    Katz J, Gryboski JD, Rosenbaum HM, Spiro HM. Dysphagia in children with epidermolysis bullosa. Gastroenterology. 1967;52:259–262.PubMedGoogle Scholar
  48. 48.
    Moynahan EJ. The treatment and management of epidermolysis bullosa. Clin Exp Dermatol. 1982; 7:665–672.PubMedGoogle Scholar
  49. 49.
    Koob TJ, Jeffrey JJ, Eisen AZ. Regulation of human skin collagenase activity by hydrocortisone and dexamethasone in organ culture. Biochem Biophys Res Commun. 1974;61:1083–1088.PubMedGoogle Scholar
  50. 50.
    Severin GL, Farber EM. The management of epidermolysis bullosa in children: effective topical steroid treatment. Arch Dermatol. 1967;95:302–309.PubMedGoogle Scholar
  51. 51.
    Wilson HD. Treatment of epidermolysis bullosa dystrophica by alpha tocopherol. Can Med Assoc J. 1964;90:1315–1316.PubMedGoogle Scholar
  52. 52.
    Ayres Jr S, Mihan R. Pseudoxanthoma elasticum and epidermolysis bullosa: response to vitamin E (tocopherol). Cutis. 1969;5:287–294.Google Scholar
  53. 53.
    Ayres Jr S, Mihan R. Vitamin E (tocopherol): a reappraisal of its value in dermatoses of mesodermal tissues. Cutis. 1971;7:35–45.Google Scholar
  54. 54.
    Sehgal VN, Sanyal RK. Vitamin E therapy in dystrophic epidermolysis bullosa (letter). Arch Dermatol. 1972; 105:460.PubMedGoogle Scholar
  55. 55.
    Sehgal VN, Vadiraj SN, Rege VL, Beohar PC. Dystrophic epidermolysis bullosa in a family: response to vitamin E (tocopherol). Dermatologica. 1972; 144:27–34.PubMedGoogle Scholar
  56. 56.
    Michaelson JD, Schmidt JD, Dresden MH, Duncan C. Vitamin E treratment of epidermolysis bullosa. Changes in tissue collagenase levels. Arch Dermatol. 1974; 109:67–69.PubMedGoogle Scholar
  57. 57.
    Bonnetblanc JM, Bouquier JJ. Response to pipamperone in case of epidermolysis bullosa herpetiformis. Lancet. 1986; 1:1327–1328.PubMedGoogle Scholar
  58. 58.
    Kahn S, Trieger N. Epidermolysis bullosa hereditaria letalis: a case report with special emphasis on oral manifestations. J Oral Med. 1976; 31:32–35.PubMedGoogle Scholar
  59. 59.
    Haber RM. Reply to the editor (letter). J Am Acad Dermatol. 1988; 18:142–143.Google Scholar
  60. 60.
    Unger WP, Nethercott JR. Epidermolysis bullosa dystrophica treated with vitamin E and oral corticosteroids. Can Med Assoc J. 1973; 108:1136–1138.PubMedGoogle Scholar
  61. 61.
    Trent WG. Epidermolysis bullosa. Arch Dermatol. 1976; 112:256.PubMedGoogle Scholar
  62. 62.
    Harper JI, Copeman PWM. Pretibial epidermolysis bullosa: the use of homograft skin dressings. Br J Dermatol. 1983; 109(Suppl 24): 60–62.Google Scholar
  63. 63.
    Ayres Jr S, Mihan R. Letter to the Editor. Dermatologica. 1973; 146:61.PubMedGoogle Scholar
  64. 64.
    Ayres Jr S, Mihan R. Vitamin E treatment of dermolytic bullous dermatosis (letter). Arch Dermatol. 1974; 109:99.PubMedGoogle Scholar
  65. 65.
    Ayres Jr S. Epidermolysis bullosa controlled by vitamin E. Int J Dermatol. 1986;25:670–671.PubMedGoogle Scholar
  66. 66.
    Fine J-D. Reply to Dr. Ayres (letter). Int J Dermatol. 1986; 25:671.Google Scholar
  67. 67.
    Reed WB. Vitamin E treatment of dermolytic bullous dermatosis (letter). Arch Dermatol. 1975; 111:524.PubMedGoogle Scholar
  68. 68.
    Smith EB, Michener W. Vitamin E treatment of dermolytic bullous dermatosis: a controlled study. Arch Dermatol. 1973; 108:254–256.PubMedGoogle Scholar
  69. 69.
    Adams RH, Main RA, Marsden RA. A controlled study of vitamin E treatment in epidermolysis bullosa. Br J Dermatol. 1975;93(Suppl 11): 10.Google Scholar
  70. 70.
    Briggaman RA, Palier AS, Pessar A. Epidermolysis bullosa. In: Provost TT, Farmer ER, eds. Current Therapy in Dermatology. Philadelphia: BC Decker; 1985:70–75.Google Scholar
  71. 71.
    Shubailat G, Oumeish OY, Amr SS. Epidermolysis bullosa dystrophica triggered by sun exposure. Ann Plast Surg. 1983; 10:239–243.PubMedGoogle Scholar
  72. 72.
    Baer TW. Epidermolysis bullosa hereditaria treated with antimalarials. Arch Dermatol. 1961;84:503–504.PubMedGoogle Scholar
  73. 73.
    Marrero L, Enriquez S, Bolat I. Epidermolysis bullosa simplex. Arch Dermatol. 1962;86:163.Google Scholar
  74. 74.
    Dorsey CS. Dystrophic epidermolysis bullosa treated with chloroquine. Arch Dermatol. 1959; 79:122.Google Scholar
  75. 75.
    Bauer EA, Seltzer JL, Eisen AZ. Inhibition of collagen degradative enzymes by retinoic acid in vitro. J Am Acad Dermatol. 1982;6:603–607.PubMedGoogle Scholar
  76. 76.
    Cooper TW, Tabas M, Bauer EA. Retinoic acid in recessive dystrophic epidermolysis bullosa: in vitro effects on collagenase and preliminary therapeutic trials. In: Saurat JH, eds. Retinoids: New Trends in Research and Therapy. New York: S. Karger, 1985:219–224.Google Scholar
  77. 77.
    Tabas M, Spraker MK. Report on the first national epidermolysis bullosa conference November 29 to December 1, 1984. Pediatr Dermatol. 1985;3:79–82.Google Scholar
  78. 78.
    Fritsch P, Klein G, Aubock J, Hintner H. Retinoid therapy of recessive dystrophic epidermolysis bullosa (letter). J Am Acad Dermatol. 1983;9:766–777.PubMedGoogle Scholar
  79. 79.
    Bauer EA, Seltzer JL, Eisen AZ. Retinoic acid inhibition of collagenase and gelatinase expression in human skin fibroblast cultures. Evidence for a dual mechanism. J Invest Dermatol. 1983; 81:162–169.PubMedGoogle Scholar
  80. 80.
    Adreano JM, Tomecki KJ. Epidermolysis bullosa simplex responding to isotretinoin (letter). Arch Dermatol. 1988; 124:1445–1446.Google Scholar
  81. 81.
    Tidman MJ, Wells RS, MacDonald DM. Epidermolysis bullosa simplex (Dowling-Meara). In: Wilkinson DS, Mascaro JM, Orfanos CE, Albers J, eds. Clinical Dermatology, The CMD Case Collection, World Congress of Dermatology. Stuttgart: Schattauer, 1987:16–17.Google Scholar
  82. 82.
    Crikelair GF, Hoehn RJ, Domonkos AN, Binkert B. Skin homografts in epidermolysis bullosa dystrophica: case report. Plast Reconstr Surg. 1970; 46:89–92.PubMedGoogle Scholar
  83. 83.
    Furue M, Ando I, Inoue Y, Tamaki K, Oohara K, Kukita A. Pretibial epidermolysis bullosa; successful therapy with a skin graft. Arch Dermatol. 1986; 122: 310–313.PubMedGoogle Scholar
  84. 84.
    Harper JI, Copeman PWM. Pretibial epidermolysis bullosa: the use of homograft skin dressings. Br J Dermatol. 1983; 109(Suppl 24): 60–62.Google Scholar
  85. 85.
    Rhymes Jr R, Hardin JC, Metts Jr D, Krantz R. Dystrophic epidermolysis bullosa: extra-articular ankylosis treated with oral skin grafts: report of a case. J Oral Surg Anesth Hosp D Serv. 1963; 21:63–67.Google Scholar
  86. 86.
    Skivolocki W, Harris BH, Boles Jr ET. A new method for skin grafting a burned patient who has epidermolysis bullosa. Plast Reconstr Surg. 1974; 53:355–357.PubMedGoogle Scholar
  87. 87.
    Carter DM, Lin AN, Varghese MC, Caldwell D, Pratt L, Eisinger M. Treatment of junctionaol epidermolysis bullosa with epidermal autografts. J Am Acad Dermatol. 1987;17:246–259.PubMedGoogle Scholar
  88. 88.
    Lin AN., Carter DM, Caldwell-Brown D. Wound healing and cultured epidermal autografts in epidermolysis bullosa. In: Priestley GC, Tidman MJ, Weiss JB, Eady RAJ, eds. Epidermolysis Bullosa: A Comprehensive Review of Classification, Management and Laboratory Studies. Crowthorne: Dystrophic Epidermolysis Bullosa Research Association; 1990:152–155.Google Scholar
  89. 89.
    McGuire J, Birchnall N, Cuono C, Moellmann G, Kuklinska E, Langdon R. Successful engraftment of allogeneic keratinocyte cultures in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 1987; 88:506.Google Scholar
  90. 90.
    Schofield OMV, Cassella J-P, Navsaria HA, Leigh IM, Mayou BJ, Eady RAJ. Cultured keratinocyte allografts indystrophic epidermolysis bullosa: preliminary observations. Br J Dermatol. 1990; 123(Suppl 37): 66.Google Scholar
  91. 91.
    Brogden RN, Pinder RM, Sawyer PR, et al. Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. Drugs. 1975;10:351–356.PubMedGoogle Scholar
  92. 92.
    Fine J-D, Johnson L. Evaluation of the efficacy of topical bufexamac in epidermolysis bullosa simplex: a double-blind placebo-controlled crossover study, Arch Dermatol. 1988;124:1669–1672.PubMedGoogle Scholar
  93. 93.
    Golub LM, McNamara TF, D’Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res. 1987; 66:1310–1314.PubMedGoogle Scholar
  94. 94.
    White JE. Minocycline for dystrophic epidermolysis bullosa (letter). Lancet. 1989;1:966.PubMedGoogle Scholar
  95. 95.
    Keller L. Silver nitrate therapy in epidermolysis bullossa hereditaria of the newborn. J Pediatr. 1968;72:854–856.PubMedGoogle Scholar
  96. 96.
    Husz S, Olah J, Korom I, Szekeres L, Kemeny E, Dobozy A. Cyclosporine for dystrophic epidermolysis bullosa (letter). Lancet. 1989;2:1393–1394.PubMedGoogle Scholar
  97. 97.
    Crow LL, Finkle JP, Gammon WR, Woodley DT. Clearing of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol. 1988; 19:937–942.PubMedGoogle Scholar
  98. 98.
    Fine J-D, Tamura T, Johnson L. Blood vitamin and trace metal levels in epidermolysis bullosa. Arch Dermatol. 1989; 125:374–379.PubMedGoogle Scholar
  99. 99.
    Cunningham-Rundles S, Bookman RS, Lin AN, Giardina PV, Hilgartner MW. Physiological and pharmacological effects of zinc on immune response Ann NY Acad Sci. 1990;587:113–122.PubMedGoogle Scholar
  100. 100.
    Weismann K. Dystrophic epidermolysis bullosa treated unsuccesfully with oral zinc (letter). Arch Dermatol Res. 1985;277:404–405.PubMedGoogle Scholar
  101. 101.
    Ikeda S, Manabe M, Muramatsu T, Takamori K, Ogawa H. Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa: in vitro effect and clinical trial with camostat mesylate. J Am Acad Dermatol. 1988; 18:1246–1252.PubMedGoogle Scholar
  102. 102.
    Hashimoto I, Katabira Y, Mitsuhashi Y, Nomura K, Hanada K. Treatment of epidermolysis bullosa with PUVA therapy. In: Orfanos CE, Stadler R, Gollnick H, eds. Dermatology in Five Continents: Proceedings of the XVII World Congress of Dermatology, Berlin, May 24–29, 1987. Berlin: Springer-Verlag; 1988:1173.Google Scholar
  103. 103.
    Matsuoka LY, Safai B. Resolution of epidermolysis bullosa following oophorohysterectomy (letter). J Am Acad Dermatol. 1980; 3:205–206.PubMedGoogle Scholar
  104. 104.
    Zackheim HS. Failure of human growth hormone to benefit dystrophic epidermolysis bullosa (letter). Arch Dermatol. 1983; 119:537.PubMedGoogle Scholar
  105. 105.
    Haber RM, Ramsay CA, Boxall LBH. Assessment of a treatment for epidermolysis bullosa (letter). Can Med Assoc J 1984; 131:10–14.PubMedGoogle Scholar
  106. 106.
    Haber RM, Ramsay CA, Boxall LBH. Epidermolysis bullosa: assessment of a treatment regimen. Int J Dermatol. 1985; 24:324–328.PubMedGoogle Scholar
  107. 107.
    Katz SI, Bauer EA, Lazarus GS, McGuire Jr JS, Briggaman RA, Sulica V. Mr. Kozak’s regime for epidermolysis bullosa (letter). J Am Acad Dermatol. 1983; 8: 565–566.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1992

Authors and Affiliations

  • Andrew N. Lin
  • D. Martin Carter

There are no affiliations available

Personalised recommendations